Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Amcor PLC (AMCR) Price & Performance

Adaptive Biotechnologies CorpTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Amcor PLC — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Amcor PLC trades at $47.23 (market cap $21.92B). The key difference: Amcor PLC is far larger — about 5.4× Adaptive Biotechnologies Corp's market cap, and Amcor PLC pays a 5.49% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTAMCR
Market Cap
$4.04B$21.92B
Sector
HealthBasic Materials
52-Week High
$25.45$50.58
52-Week Low
$12.30$36.69
Enterprise Value
$4.10B$37.03B
Dividend Yield
5.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Amcor PLC

AMCR trades at $47.24, up 0.28% today, near the analyst consensus price target of $47.00. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.23, beating estimates, with revenue growth driven by the Berry acquisition. Net income margin stands at 3.06%, while the P/E ratio of 38.07 indicates a premium valuation. Recent news highlights strong Q4 earnings and expansion in China.

The outlook for AMCR is cautiously optimistic, supported by consistent earnings beats and strategic expansions. However, elevated valuation metrics and a high RSI pose near-term risks. Investor sentiment is positive with a 64% analyst buy rating, but margin pressures and integration risks from acquisitions warrant monitoring. The stock presents a balanced opportunity with growth catalysts tempered by valuation concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Amcor PLC

Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.

Read more on AMCR